WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restrictions while a lawsuit continues. This ruling ensures that mifepristone, the medication in question, remains available to women seeking abortions, allowing them to obtain it at pharmacies or through the mail without the necessity of an in-person doctor’s visit.
The implications of this decision are significant, as it not only safeguards access to a critical healthcare option but also sets the stage for ongoing legal battles surrounding reproductive rights. With the court’s order likely to maintain uninterrupted access at least into next year, the pharmaceutical industry and healthcare providers must prepare for potential shifts in regulatory landscapes and patient care protocols as the case unfolds, including the possibility of further appeals to the Supreme Court.
Start your 7-day trial and see what the database can do →
